围手术期帕博利珠单抗治疗头颈癌的成本效果与联合阳性评分
基于KEYNOTE-689试验数据的分区生存模型模拟局部晚期头颈鳞癌围手术期帕博利珠单抗治疗的成本效果。
要点
- 生物标志物分层可指导免疫治疗的价值整合。
核心结论
- 在局部晚期HNSCC中,围手术期帕博利珠单抗对PD-L1 CPS>10患者可能具成本效果,前提是KEYNOTE-689数据可在临床实践中复现。
- 对CPS<10患者,基于当前数据围手术期帕博利珠单抗不具成本效果。
研究设计与样本
- 采用分区生存模型模拟KEYNOTE-689试验队列,设无事件生存、疾病进展和死亡三个互斥健康状态。
- 模型输入包括来自HCUP和CMS的药物获取(帕博利珠单抗和顺铂)、给药、手术、放疗、支持治疗、严重不良事件管理及疾病进展成本。
- KEYNOTE-689的Kaplan-Meier生存估计经数字化提取,CPS 1-10亚组数据由已报告的CPS≥1和CPS≥10亚组推导。
- QALY值来源于已发表文献,并将美国人群偏好权重算法应用于CheckMate 141试验的EQ-5D-3L数据。
- 主要结局为按PD-L1 CPS(1-10 vs >10)分层的增量成本效果比(ICER),并进行概率敏感性分析(PSA)。
临床怎么用
- 对于PD-L1 CPS>10的局部晚期HNSCC患者,若KEYNOTE-689数据可复现,围手术期帕博利珠单抗可视为具成本效果的干预。
- 对于CPS<10患者,基于当前数据围手术期帕博利珠单抗不具成本效果,应谨慎选择。
- 生物标志物CPS分层有助于指导HNSCC患者免疫治疗的价值整合。
局限性
- 成本效果结论依赖于KEYNOTE-689数据在临床实践中的可复现性。
- CPS 1-10亚组数据由CPS≥1和CPS≥10亚组推导而来,非直接报告。
- QALY值来源于其他试验(CheckMate 141)数据及已发表文献,可能引入不确定性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The KEYNOTE-689 trial demonstrated improved event-free survival with the addition of perioperative pembrolizumab to standard of care for patients with locally advanced head and neck squamous cell carcinoma (HNSCC), yet the cost-effectiveness remains unknown. OBJECTIVE: To evaluate the cost-effectiveness of the KEYNOTE-689 perioperative pembrolizumab protocol. DESIGN, SETTING, AND PARTICIPANTS: A partitioned survival model simulated the KEYNOTE-689 trial cohort with 3 mutually exclusive health states: event-free survival, disease progression, and death. Model inputs included Healthcare Cost and Utilization Project-derived and US Centers for Medicare & Medicaid Services-derived costs for drug acquisition (pembrolizumab and cisplatin), administration, surgery, radiation therapy, supportive care, management of serious adverse events, and disease progression. MAIN OUTCOME AND MEASURES: KEYNOTE-689 Kaplan-Meier survival estimates were digitized and data for the combined positive score (CPS) of 1 to 10 subgroup were derived from the reported CPS of 1 or greater and CPS of 10 or greater subgroups. Quality-adjusted life-year (QALY) values for different health states were sourced from published literature, with the US population preference-weighting algorithm applied to EuroQol 5-Dimension 3-Level health questionnaire data from the CheckMate 141 trial. The primary outcome was the incremental cost-effectiveness ratio (ICER) results stratified by programmed cell death 1 ligand 1 (PD-L1) combined positive score (CPS of 1 to 10 vs greater than 10). A probabilistic sensitivity analysis (PSA) was performed to evaluate parameter uncertainty. RESULTS: Subgroup analyses based on PD-L1 expression yielded divergent results. In the CPS greater than 10 cohort, perioperative pembrolizumab was cost-effective, producing approximately 1.35 additional QALYs at an incremental cost of $181 900, resulting in an ICER of $134 700. PSA showed a 57% probability that the pembrolizumab strategy was cost-effective at a $150 000 willingness-to-pay (WTP) threshold. In the CPS of 1 to 10 cohort, perioperative pembrolizumab resulted in approximately 0.08 additional QALYs at an incremental cost of $166 500, for an ICER of $2 179 400, with the PSA demonstrating an 11% probability of cost-effectiveness at a $150 000 WTP threshold. CONCLUSIONS AND RELEVANCE: In this economic evaluation, addition of perioperative pembrolizumab to standard treatment for locally advanced HNSCC may represent a cost-effective intervention for patients with a PD-L1 CPS greater than 10 if KEYNOTE-689 data are replicable in clinical practice. Perioperative pembrolizumab is not a cost-effective strategy for patients with a CPS less than 10 based on current data. Biomarker stratification may inform the value-based integration of immunotherapy among patients with HNSCC.
引用
- Coyle AH, Hutton DW, Buchakjian MR, et al. Combined Positive Score and Cost-Effectiveness of Perioperative Pembrolizumab for Head and Neck Cancer. JAMA Otolaryngol Head Neck Surg. 2026. PMID: 42560690. doi:10.1001/jamaoto.2026.2124
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。